CZ20011481A3 - Inhibitory biosyntézy prostaglandin endoperoxid H synthasy - Google Patents
Inhibitory biosyntézy prostaglandin endoperoxid H synthasyInfo
- Publication number
- CZ20011481A3 CZ20011481A3 CZ20011481A CZ20011481A CZ20011481A3 CZ 20011481 A3 CZ20011481 A3 CZ 20011481A3 CZ 20011481 A CZ20011481 A CZ 20011481A CZ 20011481 A CZ20011481 A CZ 20011481A CZ 20011481 A3 CZ20011481 A3 CZ 20011481A3
- Authority
- CZ
- Czechia
- Prior art keywords
- cox
- inhibitors
- cyclooxygenase
- biosynthesis
- synthase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17960598A | 1998-10-27 | 1998-10-27 | |
| US26187299A | 1999-03-03 | 1999-03-03 | |
| US29849099A | 1999-04-23 | 1999-04-23 | |
| US09/427,768 US6307047B1 (en) | 1997-08-22 | 1999-10-27 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ20011481A3 true CZ20011481A3 (cs) | 2001-09-12 |
| CZ300570B6 CZ300570B6 (cs) | 2009-06-17 |
Family
ID=27497355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20011481A CZ300570B6 (cs) | 1998-10-27 | 1999-10-27 | Inhibitory biosyntézy prostaglandin endoperoxid H synthasy |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124804B1 (cs) |
| JP (1) | JP2003512292A (cs) |
| KR (1) | KR100666838B1 (cs) |
| CN (1) | CN1279026C (cs) |
| AT (1) | ATE302759T1 (cs) |
| BG (1) | BG65261B1 (cs) |
| BR (1) | BR9914858A (cs) |
| CA (1) | CA2347982A1 (cs) |
| CZ (1) | CZ300570B6 (cs) |
| DE (1) | DE69926903T2 (cs) |
| DK (1) | DK1124804T3 (cs) |
| ES (1) | ES2249919T3 (cs) |
| HK (1) | HK1041876B (cs) |
| HU (1) | HUP0105248A3 (cs) |
| NO (1) | NO318623B1 (cs) |
| PL (1) | PL198503B1 (cs) |
| SK (1) | SK286806B6 (cs) |
| TR (1) | TR200101765T2 (cs) |
| WO (1) | WO2000024719A1 (cs) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU738595B2 (en) | 1997-11-19 | 2001-09-20 | Kowa Co., Ltd. | Novel pyridazine derivatives and medicines containing the same as effective ingredients |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| PT1175214E (pt) | 1999-12-08 | 2005-04-29 | Pharmacia Corp | Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| MY131964A (en) | 2000-09-15 | 2007-09-28 | Pharmacia Corp | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| US7012098B2 (en) | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| EP1490064B1 (en) | 2002-02-14 | 2009-11-18 | Pharmacia Corporation | Substituted pyridinones as modulators of p38 map kinase |
| EP1572173B1 (en) | 2002-12-13 | 2010-04-28 | Warner-Lambert Company LLC | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| EP1604984A1 (en) | 2003-03-18 | 2005-12-14 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
| PL1534305T3 (pl) | 2003-05-07 | 2007-03-30 | Osteologix As | Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| EP1916240A1 (en) * | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Pyridazine derivatives |
| CA2673545A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids |
| DE102007008840A1 (de) * | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007008839A1 (de) * | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen |
| DE102007008843A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen |
| DE102007020689A1 (de) | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP) |
| DE102007020690A1 (de) * | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| GB0716414D0 (en) * | 2007-08-22 | 2007-10-03 | Syngenta Participations Ag | Novel insecticides |
| EP2188288A1 (en) | 2007-09-11 | 2010-05-26 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| JP2012131708A (ja) * | 2009-04-28 | 2012-07-12 | Nissan Chem Ind Ltd | ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤 |
| FR2969606B1 (fr) * | 2010-12-22 | 2013-01-11 | Pf Medicament | Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| JP7096598B2 (ja) | 2016-09-07 | 2022-07-06 | トラスティーズ オブ タフツ カレッジ | イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法 |
| CN107334767B (zh) * | 2017-06-08 | 2019-03-05 | 中国医学科学院医药生物技术研究所 | 一种哒嗪酮类化合物在肿瘤治疗中的应用 |
| WO2021124344A1 (en) * | 2019-12-18 | 2021-06-24 | Abida | Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238490A (en) * | 1979-02-12 | 1980-12-09 | Diamond Shamrock Corporation | Antihypertensive pyridazin(2H)-3-ones |
| BR8108745A (pt) * | 1980-08-07 | 1982-07-06 | Diamond Shamrock Corp | Difenilpiridazinonas herbicidas e reguladores do crescimento da planta |
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| AU6269496A (en) * | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations |
| AU738727B2 (en) * | 1997-03-14 | 2001-09-27 | Merck Frosst Canada Ltd. | Pyridazinones as inhibitors of cyclooxygenase-2 |
| EP1007515A1 (en) * | 1997-08-22 | 2000-06-14 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
| AU741317B2 (en) * | 1997-08-22 | 2001-11-29 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| CA2294548A1 (en) * | 1997-08-22 | 1999-03-04 | Abbott Laboratories | Pyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
-
1999
- 1999-10-27 HU HU0105248A patent/HUP0105248A3/hu unknown
- 1999-10-27 KR KR1020017005342A patent/KR100666838B1/ko not_active Expired - Fee Related
- 1999-10-27 ES ES99953259T patent/ES2249919T3/es not_active Expired - Lifetime
- 1999-10-27 SK SK554-2001A patent/SK286806B6/sk not_active IP Right Cessation
- 1999-10-27 CN CNB998147265A patent/CN1279026C/zh not_active Expired - Fee Related
- 1999-10-27 WO PCT/US1999/025234 patent/WO2000024719A1/en not_active Ceased
- 1999-10-27 AT AT99953259T patent/ATE302759T1/de not_active IP Right Cessation
- 1999-10-27 EP EP99953259A patent/EP1124804B1/en not_active Expired - Lifetime
- 1999-10-27 PL PL349256A patent/PL198503B1/pl not_active IP Right Cessation
- 1999-10-27 BR BR9914858-7A patent/BR9914858A/pt not_active IP Right Cessation
- 1999-10-27 JP JP2000578289A patent/JP2003512292A/ja not_active Ceased
- 1999-10-27 DK DK99953259T patent/DK1124804T3/da active
- 1999-10-27 CZ CZ20011481A patent/CZ300570B6/cs not_active IP Right Cessation
- 1999-10-27 DE DE69926903T patent/DE69926903T2/de not_active Expired - Lifetime
- 1999-10-27 HK HK02101207.5A patent/HK1041876B/en not_active IP Right Cessation
- 1999-10-27 CA CA002347982A patent/CA2347982A1/en not_active Abandoned
- 1999-10-27 TR TR2001/01765T patent/TR200101765T2/xx unknown
-
2001
- 2001-04-26 NO NO20012061A patent/NO318623B1/no not_active IP Right Cessation
- 2001-05-19 BG BG105523A patent/BG65261B1/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1124804B1 (en) | 2005-08-24 |
| HUP0105248A3 (en) | 2002-09-30 |
| ATE302759T1 (de) | 2005-09-15 |
| SK5542001A3 (en) | 2001-12-03 |
| KR100666838B1 (ko) | 2007-01-11 |
| NO20012061L (no) | 2001-06-27 |
| DK1124804T3 (da) | 2005-12-12 |
| HK1041876B (en) | 2006-06-23 |
| CN1342149A (zh) | 2002-03-27 |
| HK1041876A1 (en) | 2002-07-26 |
| NO318623B1 (no) | 2005-04-18 |
| BG105523A (en) | 2001-12-29 |
| CA2347982A1 (en) | 2000-05-04 |
| PL349256A1 (en) | 2002-07-01 |
| CZ300570B6 (cs) | 2009-06-17 |
| SK286806B6 (sk) | 2009-05-07 |
| PL198503B1 (pl) | 2008-06-30 |
| DE69926903D1 (en) | 2005-09-29 |
| WO2000024719A1 (en) | 2000-05-04 |
| EP1124804A1 (en) | 2001-08-22 |
| HUP0105248A2 (hu) | 2002-07-29 |
| KR20010081101A (ko) | 2001-08-27 |
| DE69926903T2 (de) | 2006-07-13 |
| ES2249919T3 (es) | 2006-04-01 |
| TR200101765T2 (tr) | 2002-02-21 |
| BR9914858A (pt) | 2002-02-05 |
| CN1279026C (zh) | 2006-10-11 |
| NO20012061D0 (no) | 2001-04-26 |
| BG65261B1 (bg) | 2007-10-31 |
| JP2003512292A (ja) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL349256A1 (en) | Prostaglandin endoperoxide h synthase biosynthesis inhibitors | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| DE69833774D1 (en) | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren | |
| Gedawy et al. | Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors | |
| Carullo et al. | Structure–activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009–2016) | |
| Chan et al. | Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles | |
| Raz | Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)?: in vitro versus in vivo results and the relevance for the prevention and treatment of cancer | |
| Velázquez et al. | Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1, 2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies | |
| Frölich | A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes | |
| Dannhardt et al. | Cyclooxygenase inhibitors–current status and future prospects | |
| Carabaza et al. | Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs | |
| Zschocke et al. | Cryptocarya species—substitute plants for Ocotea bullata? A pharmacological investigation in terms of cyclooxygenase-1 and-2 inhibition | |
| Pairet et al. | Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs | |
| BRPI0011172B8 (pt) | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 | |
| Singh Bahia et al. | Inhibitors of microsomal prostaglandin E2 synthase‐1 enzyme as emerging anti‐inflammatory candidates | |
| EP1391201A4 (en) | MEDICAL COMPOSITIONS | |
| Petrovic et al. | Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro | |
| Ramalho et al. | The search for new COX-2 inhibitors: a review of 2002–2008 patents | |
| Naureen et al. | Discovery of indole-based tetraarylimidazoles as potent inhibitors of urease with low antilipoxygenase activity | |
| Zhu et al. | Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats | |
| Ma et al. | Promoter methylation regulates cyclooxygenase expression in breast cancer | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| Narayan et al. | Role of Pterocarpus santalinus against mitochondrial dysfunction and membrane lipid changes induced by ulcerogens in rat gastric mucosa | |
| Tavares | The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa | |
| Kim et al. | Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20101027 |